Gastroenterology Unit, Department of Internal Medicine, University of Genoa, 16132, Genoa, Italy, email@example.com.
13C-Aminopyrine breath test (13C-ABT) is a non-invasive, dynamic, quantitative liver function test, and the model for end-stage liver disease (MELD) is a recognised biochemical score used to predict survival in patients with cirrhosis.
The purpose of this study was to evaluate the relationship between the 13C-ABT and MELD score in a cohort of cirrhotic patients and, moreover, to assess the prognostic value of 13C-ABT results in the same group of patients.
PATIENTS AND METHODS:
Forty-six patients with cirrhosis and without hepatocellular carcinoma who underwent 13C-ABT and who had at least 1-year follow-up were prospectively included in this study. MELD score was calculated at entry into the study in all patients. End-points of the study were 1-year liver-related death or liver transplantation.
13C-ABT %dose/h at 30 min (%dose/h30) results showed significant, inverse correlation with MELD scores (r = -0.414, P = 0.004). During 1-year follow-up nine patients died (19.6 %) and two were transplanted (4.3 %). Median 13C-ABT %dose/h30 results (3.2 vs. 1.8) were significantly higher in patients who survived as compared to those who died or underwent transplantation (P = 0.04). Receiver operating characteristics curves showed that a 13C-ABT %dose/h30 cut-off of 2.0 had the best accuracy (c-index = 0.717) in assessing 1-year prognosis.
We observed a correlation between a flow-independent quantitative liver function test and the MELD score, and found that the 13C-ABT may accurately provide long-term prognostic information in cirrhotic patients.